梅斯医学与西安杨森爱可泰隆签署战略合作,共同推动罕见病领域认知与诊疗水平

2021-11-18 JACKZHAO MedSci原创

梅斯医学与强生旗下杨森医药公司爱可泰隆签署了双方深度学术战略合作协议。双方宣布在满足各自战略发展理念的前提下,缔结战略合作关系,共同探索商业发展新模式,推动中国罕见病领域的疾病认知水平和诊疗水平

梅斯医学与强生旗下杨森医药公司爱可泰隆签署了双方深度学术战略合作协议

2021年11月18日,上海,梅斯医学与强生旗下杨森医药公司爱可泰隆签署了双方深度学术战略合作协议双方宣布在满足各自战略发展理念的前提下,缔结战略合作关系,共同探索商业发展新模式,增强并推动中国罕见病领域的疾病认知水平和诊疗水平提升。

双方本着“依法合规、优势互补、互惠互利、风险共担”的基本原则,梅斯医学与强生旗下杨森医药公司爱可泰隆一致同意发挥各自领域的资源优势和比较优势,双方合作的内容包含并不仅限于肺动脉高压领域的全国学术平台搭建、转诊模式设计、虚拟代表赋能、数字化医患教育、市场信息调研等领域的深度合作

肺动脉高压(pulmonary hypertension, PH)是指由多种异源性疾病(病因)和不同发病机制所致肺血管结构或功能改变,引起肺血管阻力和肺动脉压力升高的临床和病理生理综合征,继而发展成右心衰竭甚至死亡。因预后与某些癌症类似,故有人称之为“心血管疾病中的癌症”。

爱可泰隆是肺动脉高压领域的市场领导者,其肺动脉高压治疗产品涵盖从WHO功能分级II级到IV级的疾病全过程,包括口服、吸入和静脉制剂。2019年,爱可泰隆宣布波生坦分散片获得国家药品监督管理局批准用于治疗儿童肺动脉高压。波生坦分散片由此成为国内首个获批的儿童肺动脉高压患者用药。

在过去二十年期间,爱可泰隆的产品显著帮助了广大肺动脉高压患者改善预后和生活质量。杨森公司现已将肺动脉高压纳入重点治疗领域,以巩固并扩大爱可泰隆在该领域的领先地位。

梅斯医学是国内知名的专业的临床研究平台,具有雄厚学术与科研学术服务能力积累,能够提供重要的外部资源与智力支持。梅斯医学是医药数字化的早期入局者,近20年在医药数字化领域不断探索布局,并取得诸多成果,已经成长成为成为领先的数字化临床研究和医学学术传播平台。给国内外上百家知名的药企和器械公司提供全方位医疗数字营销解决方案。

该深度学术合作签约将加速推动我国引进肺动脉高压治疗方案,服务广大中国患者。为中国临床实践提供更多的中国本土化的临床证据,共同推动罕见病领域认知与诊疗水平。

 

----

关于强生旗下杨森制药公司爱可泰隆

2017年6月,爱可泰隆加入强生旗下杨森制药公司。爱可泰隆公司总部位于瑞士巴塞尔州阿尔施维尔市。爱可泰隆是肺动脉高压领域的市场领导者,其肺动脉高压治疗产品涵盖从WHO功能分级II级到IV级的疾病全过程,包括口服、吸入和静脉制剂。在过去二十年期间,爱可泰隆的产品显著帮助了广大肺动脉高压患者改善预后和生活质量。杨森公司现已将肺动脉高压纳入重点治疗领域,以巩固并扩大爱可泰隆在该领域的领先地位。

关于梅斯医学:

梅斯医学( MedSci )是面向医生的综合互联网平台,应用大数据和人工智能技术链接医生、患者、药械企业等,提供精准数字化医学传播解决方案,优化医疗生态,改善医疗质量,共创美好健康生活。

梅斯医学主要产品包括数字化医学传播和数字化临床研究,涵盖临床研究、医生职业成长、多渠道学术传播、智慧医疗等类别。在数字化临床研究层面,提供临床研究整体解决方案,通过数字化技术降低成推本,提升质量;在数字化医学传播方面,提供数字化的专业医学内容和精准、整合的传播方案,将最新的技术与知识精准地传递给目标医生。 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2023351, encodeId=9fca202335191, content=<a href='/topic/show?id=39de91e07b7' target=_blank style='color:#2F92EE;'>#诊疗水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91707, encryptionId=39de91e07b7, topicName=诊疗水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Tue Dec 21 23:04:38 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277287, encodeId=629c12e72873f, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424983, encodeId=aad51424983e2, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90494, encryptionId=d42b90494af, topicName=西安杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a73942387, createdName=qindq, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467635, encodeId=19bd146e635ee, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478285, encodeId=8ec914e82859d, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543230, encodeId=35541543230d5, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61592, encryptionId=f2be61592eb, topicName=杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=421413558235, createdName=陆成振, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2023351, encodeId=9fca202335191, content=<a href='/topic/show?id=39de91e07b7' target=_blank style='color:#2F92EE;'>#诊疗水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91707, encryptionId=39de91e07b7, topicName=诊疗水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Tue Dec 21 23:04:38 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277287, encodeId=629c12e72873f, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424983, encodeId=aad51424983e2, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90494, encryptionId=d42b90494af, topicName=西安杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a73942387, createdName=qindq, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467635, encodeId=19bd146e635ee, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478285, encodeId=8ec914e82859d, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543230, encodeId=35541543230d5, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61592, encryptionId=f2be61592eb, topicName=杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=421413558235, createdName=陆成振, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
    2021-11-20 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=2023351, encodeId=9fca202335191, content=<a href='/topic/show?id=39de91e07b7' target=_blank style='color:#2F92EE;'>#诊疗水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91707, encryptionId=39de91e07b7, topicName=诊疗水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Tue Dec 21 23:04:38 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277287, encodeId=629c12e72873f, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424983, encodeId=aad51424983e2, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90494, encryptionId=d42b90494af, topicName=西安杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a73942387, createdName=qindq, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467635, encodeId=19bd146e635ee, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478285, encodeId=8ec914e82859d, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543230, encodeId=35541543230d5, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61592, encryptionId=f2be61592eb, topicName=杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=421413558235, createdName=陆成振, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2023351, encodeId=9fca202335191, content=<a href='/topic/show?id=39de91e07b7' target=_blank style='color:#2F92EE;'>#诊疗水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91707, encryptionId=39de91e07b7, topicName=诊疗水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Tue Dec 21 23:04:38 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277287, encodeId=629c12e72873f, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424983, encodeId=aad51424983e2, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90494, encryptionId=d42b90494af, topicName=西安杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a73942387, createdName=qindq, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467635, encodeId=19bd146e635ee, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478285, encodeId=8ec914e82859d, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543230, encodeId=35541543230d5, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61592, encryptionId=f2be61592eb, topicName=杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=421413558235, createdName=陆成振, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
    2021-11-20 syscxl
  5. [GetPortalCommentsPageByObjectIdResponse(id=2023351, encodeId=9fca202335191, content=<a href='/topic/show?id=39de91e07b7' target=_blank style='color:#2F92EE;'>#诊疗水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91707, encryptionId=39de91e07b7, topicName=诊疗水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Tue Dec 21 23:04:38 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277287, encodeId=629c12e72873f, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424983, encodeId=aad51424983e2, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90494, encryptionId=d42b90494af, topicName=西安杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a73942387, createdName=qindq, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467635, encodeId=19bd146e635ee, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478285, encodeId=8ec914e82859d, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543230, encodeId=35541543230d5, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61592, encryptionId=f2be61592eb, topicName=杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=421413558235, createdName=陆成振, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2023351, encodeId=9fca202335191, content=<a href='/topic/show?id=39de91e07b7' target=_blank style='color:#2F92EE;'>#诊疗水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91707, encryptionId=39de91e07b7, topicName=诊疗水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Tue Dec 21 23:04:38 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277287, encodeId=629c12e72873f, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424983, encodeId=aad51424983e2, content=<a href='/topic/show?id=d42b90494af' target=_blank style='color:#2F92EE;'>#西安杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90494, encryptionId=d42b90494af, topicName=西安杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a73942387, createdName=qindq, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467635, encodeId=19bd146e635ee, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478285, encodeId=8ec914e82859d, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543230, encodeId=35541543230d5, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61592, encryptionId=f2be61592eb, topicName=杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=421413558235, createdName=陆成振, createdTime=Sat Nov 20 04:04:38 CST 2021, time=2021-11-20, status=1, ipAttribution=)]
    2021-11-20 陆成振

相关资讯

生物信息学分析揭示了肺动脉高压的标志基因和潜在的治疗靶点

肺动脉高压(PAH)是一种罕见的心血管疾病,死亡率非常高。目前可用的治疗策略可以改善症状,但不能从根本上逆转病情。CDC5L和DDX46可能是 PAH 的标记基因和潜在的治疗靶点。

Eur Respir J:右心房功能与右心室舒张僵硬度相关:肺动脉高压中右心房-右心室的相互作用

肺动脉高压 (PAH) 患者的右心房 (RA) 功能和右心室 (RV) 舒张期硬度发生了改变。本研究评估了 RV 舒张期硬度对 RA-RV 相互作用的影响。

细胞色素 P450 环氧合酶2J2保护肺动脉高压和肺缺血再灌注损伤

细胞色素 P450 环氧合酶 2J2 (CYP2J2) 将花生四烯酸代谢为环氧二十碳三烯酸 (EET),其对心血管系统发挥抗炎、抗凋亡、促增殖和抗氧化作用。同样,其在肺动脉高压中具有保护作用。

Front Cardiovasc Med:肺动脉高压的新型预后预测因子:血尿素氮

特发性肺动脉高压(IPAH)是一种危及生命的疾病,死亡率增加。尿素循环途径在IPAH的严重程度和治疗反应中起主要作用。血尿素氮 (BUN) 可作为IPAH预后的预测因子。

大麻素—肺动脉高压辅助治疗的新视角

目前,没有任何治疗方法可以完全治愈肺动脉高压 (PH),肺动脉高压会导致右心室衰竭,从而导致死亡。大麻素是一组与大麻素受体相互作用的亲脂性化合物,大麻素对肺循环和 PH 的潜在有益影响。

基于右心室功能的肺动脉高压患者无创风险预测

右心室功能障碍是肺动脉高压 (PAH) 结局的主要决定因素。我们旨在确定与不良结果相关的超声心动图右心参数,并为 PAH 患者开发一种基于超声心动图的无创风险评分。